Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$38.21M$38.21M+16.5% vs Q3 2024 Net Income-$17.50M-$17.50MN/M vs Q3 2024 EPS Diluted-$0.10-$0.10N/M vs Q3 2024 Gross Profit$26,299,000+12.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,331,000−60.5% Free Cash Flowderived$1,331,000−54.7% Margins · derivedGross margin68.8%−2.4 pt vs Q3 2024
Operating margin-10.7%+2.9 pt vs Q3 2024
Net margin-45.8%−31.0 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 4, 2025 · 35 d after period end